[Form 4] MiNK Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

MiNK Therapeutics director Robert Peter Kadlec was granted a stock option to buy 3,225 shares of common stock at an exercise price of $15.36 per share on 09/09/2025. The option is an award that vests in full on the one-year anniversary of the grant date if Mr. Kadlec remains on the board and expires on 09/09/2035. The Form 4 was filed for the reporting person identified at a New York address and signed by an attorney-in-fact on 09/11/2025. No cash proceeds were reported at the time of filing.

Positive

• Equity alignment: Grant ties director compensation to company stock performance via options.
• Clear vesting: Option vests in full after one year, conditioned on continued board service.
• Long exercise window: Ten-year term to expiration through 09/09/2035, giving time for value realization.

Negative

• None.

Insights

Financial Analyst

TL;DR: Routine director equity grant of 3,225 options at $15.36; modest alignment with long-term incentives, neutral near-term impact.

The grant awards the director the right to purchase 3,225 shares at $15.36, vesting in full after one year of continued board service and expiring in 2035. This is a standard form of non-derivative compensation for board members intended to align interests with shareholders. The size and terms disclosed are specific but the filing contains no information on percentage ownership, pro forma dilution, or immediate cash impact, limiting conclusions about material financial effect.

Corporate Governance Expert

TL;DR: Typical governance practice: time-based vesting aligns director incentives; disclosure is straightforward and compliant.

The Form 4 shows clear grant terms and a one-year cliff vesting condition tied to continued board service, which is a common governance safeguard. The long ten-year expiration provides a wide exercise window. The filing is administrative and consistent with routine board compensation disclosures; it does not indicate departures, policy changes, or related-party transactions beyond the normal director award.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kadlec Robert Peter

(Last) (First) (Middle)

149 FIFTH AVENUE, SUITE 500

(Street)

NEW YORK NY 10010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MiNK Therapeutics, Inc. [ INKT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$15.36	09/09/2025		A		3,225		(1)	09/09/2035	Common Stock	3,225	$0	3,225	D

Explanation of Responses:

1. The option vests in full on the one-year anniversary of the date of grant, provided that the Reporting Person continues to serve on the Issuer's Board of Directors through such date.

	By: /s/ Christine Klaskin, Attorney-in-Fact	09/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did MiNK Therapeutics (INKT) disclose in this Form 4?

The company disclosed a grant of a stock option to director Robert Peter Kadlec to buy 3,225 shares at an exercise price of $15.36, granted on 09/09/2025.

When does the option vest and when does it expire?

The option vests in full on the one-year anniversary of the grant if the reporting person remains a director and it expires on 09/09/2035.

Did the Form 4 report any cash proceeds from the transaction?

No cash proceeds were reported in the filing; the Form 4 records the grant of the option rather than an exercised sale.

Who filed the Form 4 for Robert Peter Kadlec?

The filing lists Robert Peter Kadlec as the reporting person and the signature block shows the form was signed by an attorney-in-fact, Christine Klaskin, on 09/11/2025.

What is the exercise price per share for the option?

The exercise price is $15.36 per share for the 3,225-share option award.